KPM Tech Applies for IND Approval for Bridge Clinical Trial of COVID-19 Treatment
[Asia Economy Reporter Minji Lee] KPMTec announced on the 25th that it has applied to the Ministry of Food and Drug Safety for approval of an Investigational New Drug (IND) application for a bridging clinical trial of the novel coronavirus disease (COVID-19) treatment Lenzilumab.
Hot Picks Today
600 Million vs. 460 Million vs. 160 Million... Samsung Electronics DS Division: "Three Paychecks Under One Roof"
- Opening a Bank Account in Korea Is Too Difficult..."Over 150,000 Won in Notarization Fees Just for a Child's Account and Debit Card" [Foreigner K-Finance Status]②
- Samsung Labor-Management Strikes Dramatic Deal, But Issues Remain... 'Division Fairness and Operating Profit Link' Domino Effect
- "Disappointing Results: 80% of Sunscreens Found Lacking in Safety and Effectiveness"
- "Who Is Visiting Japan These Days?" The Once-Crowded Tourist Spots Empty Out... What's Happening?
The company stated, "We will evaluate the safety, tolerability, and pharmacokinetic characteristics of intravenous administration of Lenzilumab in domestic adults," adding, "Subsequently, we will comparatively assess the safety, tolerability, and pharmacokinetic characteristics with those of Western populations."
This content was produced with the assistance of AI translation services.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
!["Please Help Us": How Much Do Those Bowing Deeply for Your Vote Really Earn? [Data Pick]](https://cwcontent.asiae.co.kr/asiaresize/307/2026052010120870131_1779239528.png)
